Articles tagged "Histocompatibility antigens"

2019 American Transplant Congress
Emergence of Anti-HLA Antibodies after Catch-Up Vaccinations in Pediatric Kidney Transplant Candidates
H. Sweiss¹, J. Lyons¹, D. Ranch², K. Hitchman², E. Kincaide¹, B. Crowther¹
¹University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ²University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: Evaluate anti-HLA antibody (Ab) emergence after catch-up vaccinations in pediatric kidney transplant candidates (PKTC).*Methods: A single center retrospective review of PKTC 25% from baseline,…
2019 American Transplant Congress
Predicted Indirectly Recognizable H L A Epitopes Are Associated with T-cell Mediated Rejection among Kidney Transplant Recipients with Preformed and De Novo Donor-Reactive T-cells
T. Schachtner¹, M. Stein², N. M. Otto³, P. M. Reinke²
¹Nephrology, University Hospital Zurich, Zurich, Switzerland, ²Berlin-Brandenburg Center for Regenerative Therapies, Charite University Medicine Berlin, Berlin, Germany, ³Berlin-Brandenburg Center for Regenerative Therapies, Charite University Medicine Berlin, Berin, Germany
*Purpose: Very recently Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) have been suggested to demonstrate early and late effects on kidney allograft outcomes. The association between…
2019 American Transplant Congress
Non-HLA Antibodies against Structural and Non-Structural Target in C4d Negative Antibody Mediated Rejections after Renal Transplantation
S. Kanangat¹, I. Kurbegovic-Skaljic², D. Cimbaluk², M. Oppermann², S. Jensik³, E. Hollinger³, O. Olaitan⁴, R. DeCresce²
¹Tumor Immunology, NIH/NCI Bethesda MD,USA, Bethesda, MD, ²Pathology, Rush University Medical Center, Chicago, IL, ³Surgery, Rush University Medical Center, Chicago, IL, ⁴Tumor Immunology, Rush University Medical Center, Chicago, IL
*Purpose: According to the latest Banff’s criteria approved in 2003, antibody mediated rejections following renal transplantation are divided into 2 types namely C4d + and…
2019 American Transplant Congress
Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?
J. O. Paixão, L. R. Ulisses, P. S. Souza, G. Bezerra, F. Agena, H. P. Rodrgues, N. Panajotopoulos, F. J. Paula, E. David-Neto, M. R. Castro
Nefrologia, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil
*Purpose: The reduction of anti-HLA has been proven to be efficient and safe in transplants of highly-sensitized with living donors (LD). The results of adopting…
2019 American Transplant Congress
Towards Human Leukocyte Antigen Immunogenicity Assessment at the Individual Patient Level
H. Copley¹, H. McDowell², D. Pinelli², A. R. Tambur², V. Kosmoliaptsis¹
¹Department of Surgery, University of Cambridge, Cambridge, United Kingdom, ²Department of Surgery, Feinberg School of Medicine, Comprehensive Transplant Center, Northwestern University, Chicago, IL
*Purpose: Allorecognition of donor HLA and induction of humoral alloimmunity is a major cause of graft loss after solid-organ transplantation. Current approaches to study molecular…
2018 American Transplant Congress
The Impact of Duration on Dialysis on the Pre-Transplant Allosensitization According to Panel Reactive Antibody Levels
Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,² J. Lee,³ B. Kim,⁴ J. Lee,¹ S. Kim,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, College of Medicine, Ewha Women's University, Seoul, Republic of Korea; ³Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; ⁴Departments of Nephrology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose : Presensitization to human leukocyte antigen(HLA) is one of the most important barriers to overcome in the field of renal transplantation. Due to the…
2018 American Transplant Congress
Selection and Stratification of Anti-HLA-A and HLA-B Sensitized Patients in Pig-to-Human Xenotransplantation
G. Martens,¹ J. Ladowski,¹ J. Butler,² L. Reyes,¹ M. Tector,¹ A. Tector.¹
¹University of Alabama at Birmingham, Birmingham, AL; ²Indiana University School of Medicine, Indianapolis, IN.
Introduction: Patients with anti-HLA-A and –B antibodies are difficult to match and represent a possible population for inclusion in pig-to-human xenotransplantation clinical trials. Donor specific…
2018 American Transplant Congress
Generation of Calculated Panel-Reactive Antibody Values Using a Reference Panel of Bone Marrow Donors
E. Kransdorf,¹ L. Gragert,^2,4 M. Pando,³ N. Kaur,² J. Patel,¹ I. Kim,¹ X. Zhang,¹ M. Maiers,⁴ J. Kobashigawa.¹
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²Tulane University School of Medicine, New Orleans, LA; ³Baylor Scott & White, Temple, TX; ⁴National Marrow Donor Program, Minneapolis, MN.
Introduction: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. The reference…
2018 American Transplant Congress
Correlation of Kidney Transplant Human Leukocyte Antigen Eplet Mismatching to De Novo Donor Specific Antibody Production and Post-Transplant Outcomes
R. Samudralwar,¹ K. Szempruch,¹ C. Reuter,³ B. Franz,⁴ R. Lee,¹ E. Weimer,⁴ R. Detwiler,² T. Kozlowski,² J. Schmitz.⁴
¹Department of Pharmacy, Universitty of North Carolina Medical Center, Chapel Hill, NC; ²Department of Surgery, Universitty of North Carolina Medical Center, Chapel Hill, NC; ³Department of Pharmacy, Ochsner Health System, New Orleans, LA; ⁴Department of Pathology, University of North Carolina Medical Center, Chapel Hill, NC.
Human Leukocyte Antigen (HLA) eplet mismatches (EMM) are associated with the development of de novo donor specific antibody (dnDSA) in kidney transplant recipients (KTRs). There…
2017 American Transplant Congress
Immunosuppression and Graft Rejection in Living-Related HLA-Identical Renal Transplantation.
R. Ossman,¹ M. Jamme,¹ P. Galichon,¹ A. Hertig,¹ B. Moulin,² C. Legendre,³ E. Morelon,⁴ J.-L. Taupin,⁵ L. Rostaing,⁶ E. Rondeau.¹
¹Urgences Néphrologiques et Transplantation, Hôpital Tenon, RADOVFULL Study Group, Université Pierre et Marie Curie, Paris, France; ²Néphrologie et Transplantation, Hôpital Civil, Strasbourg, France; ³Néphrologie et Transplantation, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France; ⁴Néphrologie et Transplantation, Hôpital Edouard Herriot, Université de Lyon, Lyon, France; ⁵Laboratoire d'Histocompatibilité, Hôpital Saint-Louis, Université Paris Diderot, Paris, France; ⁶Néphrologie et Transplantation d'Organes, Université Paul Sabatier, Toulouse, France
Purpose: We aimed to describe the immunosuppressive regimens and graft rejection rates in living-related HLA-identical (LR HLAid) renal transplantation.Methods: We performed a retrospective multicenter analysis…